Treatment of early-stage HER2+ breast cancer-an evolving field.
The evolving field of HER2-targeted therapy has significantly improved the outcome of women diagnosed with HER2-positive invasive breast cancer. In this review, we sought to summarise the efficacy of trastuzumab-based regimens in the adjuvant and neoadjuvant setting with a special emphasis on relevant clinical questions: treatment duration, sequence of trastuzumab administration, toxicity, the role of anthracycline-based regimens, and optimal management of small HER2+ tumours. Controversial topics are discussed taking into consideration the development of modern anti-HER2 agents.
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA ; Hospital de Santa Maria and Instituto de Medicina Molecular, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-035-Lisbon, Portugal.
Arlindo R
AR
Ferreira
Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000, Brussels, Belgium.
Kamal S
KS
Saini
Dana-Farber Cancer Institute, 450 Brookline Ave, Boston MA 02215, USA.
Otto
O
Metzger-Filho
adjuvant therapy; antibodies, monoclonal, humanised; breast neoplasm; neoadjuvant therapy; trastuzumab